Key Highlights
● Second-quarter revenue rose 5.3% to $350.5 million, or 11.0% excluding a lapsed client.
● Net income was $28.1 million, or $0.34 per diluted share.
● Gross margin was 25.5%, up from 23.7%.
● Progyny repurchased about 1.2 million shares for $31.5 million in the quarter.
Progyny, Inc. (NASDAQ:PGNY), the fertility and family-building benefits manager, is now guiding to a modest but profitable 2026, and the figures behind that guidance invite a valuation-minded question. Second-quarter revenue rose 5.3% to $350.5 million, yet excluding a large client that did not renew, growth was 11.0%.
Latest Company Context
For the quarter ended June 30, 2026, Progyny reported revenue of $350.5 million, gross margin of 25.5% (up from 23.7%), and net income of $28.1 million, or $0.34 per diluted share, versus $0.19 a year earlier. Adjusted EBITDA was $62.1 million, up 7.2%, and adjusted EPS was $0.55 against $0.48.
Operating cash flow was $50.4 million, slightly below the $55.5 million of the prior-year quarter. The company ended the period with $236.9 million of cash, cash equivalents and marketable securities, no debt and an undrawn $200 million revolver. It served 604 fertility and family-building clients, up from 542 a year earlier.
Key Business and Index Drivers
Three forces appear to be shaping per-share results. The first is the client mix. The headline growth rate is held down by the non-renewal of a large client, while underlying growth is stronger, so comparisons may normalize as that effect rolls off.
The second is margin. A 180 basis point gross margin gain in a year, helped net income rise from $17.1 million to $28.1 million. Sustaining such gains may depend on how utilization of fertility benefits and treatment costs evolve.
The third is capital return. The company repurchased about 1.2 million shares for $31.5 million in the quarter. Under the May 2026 program, 2 million shares have been bought, with about $142.5 million of the $200 million authorization remaining. Aggregate purchases under the May 2026 and November 2025 programs total 10.8 million shares, which can lift earnings per share even when net income grows slowly.
What Investors Should Watch
Company guidance for 2026 is revenue of $1.360 billion to $1.385 billion, net income of $104.8 million to $109.9 million, adjusted EBITDA of $233.0 million to $240.0 million and adjusted EPS of $2.04 to $2.10. For the third quarter, it guides to revenue of $335 million to $345 million, adjusted EBITDA of $56 million to $59 million and adjusted EPS of $0.50 to $0.52.
Points that may matter include:
● Third-quarter revenue guidance sits below the second-quarter result, so the pattern of seasonality and utilization could be closely watched.
● Fall selling-season outcomes, which management described as favorable so far.
● Pace of the remaining buyback authorization.
● Whether cash flow tracks earnings, given the modest decline in quarterly operating cash flow.
Guidance reflects management's expectations; the third-quarter report date is unconfirmed.
Lapsed Client Effects and Per-Share Lift
Progyny presents a profile of steady, mid-single-digit reported growth supported by margin gains, a net cash balance and sizeable repurchases. How the market values that combination may depend on whether underlying growth near the low double digits persists as the lapsed client effect fades, and on whether margins hold.






Please wait processing your request...